Rise Therapeutics Showcases Promising R-3750 Results at DDW Conference in San Diego

Rise Therapeutics Unveils R-3750 Clinical Results at DDW Conference

During the recent Digestive Disease Week (DDW) conference held in San Diego from May 3 to May 6, Rise Therapeutics announced its first clinical findings from the dose escalation phase of the R-3750 Phase 1 trial, focused on treating ulcerative colitis. This biopharmaceutical company specializes in developing precision immunotherapies and aims to address the chronic illness that impacts millions worldwide.

Overview of R-3750

R-3750 represents a novel approach towards treating Inflammatory Bowel Disease (IBD), incorporating synthetic biology to create an oral immunotherapy targeting specific dendritic cells. This treatment offers great promise due to its unique action mechanism aimed at addressing the foundational immunological issues associated with gastrointestinal inflammatory diseases. In IBD, the underlying problem is a dysfunctional immune response, which can lead to debilitating symptoms and significant quality of life reduction.

Extensive preclinical studies of R-3750 have highlighted its ability to specifically target a receptor on dendritic cells, which helps stimulate regulatory T cells (Tregs) that mitigate gut inflammation and enhance the integrity of the gut barrier. Such an innovative mechanism positions R-3750 as a pioneering therapy within its class, poised to offer real hope for patients suffering from IBD.

Clinical Highlights

At the DDW conference, Dr. Christian Furlan Freguia, Senior Vice President of Research and Development at Rise Therapeutics, presented the safety, tolerability, and clinical effectiveness results of R-3750 in patients diagnosed with mild to moderate ulcerative colitis. Attendees were invited to hear Dr. Freguia’s insights during his presentation on May 6 at 10:30 AM PT.

Gary Fanger, President and CEO of Rise Therapeutics, expressed gratitude for the opportunity to present the company’s groundbreaking findings. He emphasized that these results signify a significant breakthrough not just for R-3750, but for creating a new class of Oral Immune Biomodulator therapies that aim to reeducate the immune repertoire to address the root causes of inflammatory diseases.

Fanger stated, “This an important milestone demonstrating the potential for this new class of Oral Immune Biomodulator therapies that reeducate immunological repertoires to treat root cause of inflammatory disease.” He acknowledged the dedicated team at Rise for their commitment to advancing R-3750 and expanding their pipeline of Oral Immune Biomodulator drugs.

Understanding Ulcerative Colitis

Ulcerative colitis is a chronic condition characterized by inflammation of the gastrointestinal lining, often leading to the development of ulcers. The malfunctioning immune system plays a pivotal role in the pathology of this disease, affecting an estimated 4.9 million individuals globally, with a worrying rise in cases among those under 18.

Most available treatments for IBD revolve around immunosuppression which, while somewhat effective, carry risks of severe side effects and are complicated by difficult modes of administration. Unfortunately, many patients find themselves lacking satisfactory treatment options, which highlights the critical need for innovative solutions like R-3750.

About Rise Therapeutics

Rise Therapeutics is pioneering the development of first-in-class Oral Immune Biomodulators aimed at treating autoimmune diseases and cancer. By utilizing an integrated infrastructure for product development, the company is well-positioned to bring innovative therapies to market. R-3750 is just one example of how Rise Therapeutics is leveraging cutting-edge science to transition from concept to clinical proof.

For further information on Rise Therapeutics and their projects, please visit risetherapeutics.com.